Evgen Pharma PLC First Patient Dosed in Breast Cancer Trial (3010U)
17 Gennaio 2017 - 8:00AM
UK Regulatory
TIDMEVG
RNS Number : 3010U
Evgen Pharma PLC
17 January 2017
For immediate release 17 January 2017
Evgen Pharma plc
("Evgen Pharma" or "the Company")
First Patient Dosed in Phase II Breast Cancer Trial
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, is pleased to announce that the first patient has been
dosed in the Company's Phase II clinical trial of SFX-01 in breast
cancer.
The STEM (SFX-01 in the Treatment and Evaluation of Metastatic
Breast Cancer) trial is investigating SFX-01 in combination with
different hormone-based therapies in 60 metastatic breast cancer
patients whose cancer cells are estrogen-receptor positive (ER+).
The primary objectives of the STEM trial are to evaluate safety and
efficacy (via tumour imaging) in patients starting to become
resistant to mainstream hormone therapy. Patients will be enrolled
into one of three study arms (SFX-01 in combination with either
aromatase inhibitors, tamoxifen or fulvestrant) based on their
current therapy.
The STEM trial is being led by Chief Investigator Dr Sacha
Howell at Manchester's Christie NHS Foundation Trust, Europe's
largest single-site cancer centre, and will include approximately
15 sites in 5 countries.
The first patient was dosed on 16 January 2017 at the Cliniques
universitaires Saint-Luc, the largest hospital in Brussels,
Belgium.
One proposed mechanism for the generation of resistance to
hormone therapy is via the proliferation of hormone-independent
breast cancer stem cells. Such cells are known to proliferate
during treatment with hormonal agents and it is thought they could
have the effect of repopulating the tumour to render it
hormone-independent. Earlier work by the Company with xenograft
models suggests that SFX-01 has the effect of reducing the number
of hormone-independent cancer stem cells.
SFX-01 is a synthetic and stabilised version of the naturally
occurring plant compound sulforaphane, a known anti-cancer agent
and neuro-protective.
Dr Stephen Franklin, CEO of Evgen Pharma, commented: "The first
patient being dosed in this Phase II trial of SFX-01 in breast
cancer is another major milestone for Evgen Pharma. We would like
to thank all of the investigators and sites participating in this
exciting trial, which is seeking to demonstrate that SFX-01 is
safe, well tolerated and can positively impact the resistance to
hormone-based therapy in metastatic breast cancer patients."
Enquiries:
Evgen Pharma plc c/o +44 (0) 20
Dr Stephen Franklin, CEO 7466 5000
www.evgen.com
Buchanan
Mark Court, Sophie Cowles, Stephanie +44 (0) 20
Watson 7466 5000
Northland Capital Partners Limited
Matthew Johnson, Gerry Beaney, Margarita
Mitropoulou (Corporate Finance) +44 (0) 20
John Howes, Rob Rees (Corporate Broking) 3861 6625
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. It is also carrying out preclinical work in
multiple sclerosis and has a clinical interest in prostate cancer.
The Company's core technology is Sulforadex(R), a method for
synthesising and stabilising the naturally occurring compound
sulforaphane and novel proprietary analogues based on sulforaphane.
The lead product, SFX-01, is a patented composition of synthetic
sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and is based
in Liverpool, UK, at the Liverpool Science Park. It joined the AIM
market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information please visit www.evgen.com.
For a recent analyst research note on Evgen Pharma, please
visit:
http://www.hardmanandco.com/docs/default-source/company-docs/evgen-pharma-documents/29.11.16-harnessing-the-clinical-potential-of-sulforaphane.pdf
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESGGUPAGUPMPGQ
(END) Dow Jones Newswires
January 17, 2017 02:00 ET (07:00 GMT)
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Lug 2023 a Lug 2024